In continuation of the last year's special issue "TCM Zheng Classification and Clinical Trials, " the time for 2014 issue has come. Now we are on the way from TCM Zheng classification in clinical trial to development of clinical practice guideline.
Clinical effectiveness is what matters most in any treatment, including traditional Chinese medicine (TCM). Many clinical trials have been conducted in China to evaluate the effectiveness of TCM, but many of the studies are with poor quality and may be inaccessible to non-Chinese scientists. As shown in Figure 1 , the number of randomized controlled trials (RCTs) for TCM is small in PubMed database. The situation may be partly due to the methodological difficulties, such as trial design and implementation of blinded trials of TCM Zheng classification (Bian Zheng, syndrome differentiation) treatments. These facts and figure illustrate that the present special issue focuses on an intractable topic in TCM research.
This 2014 special issue contains 9 articles accepted from a total of 19 submissions consisting of 6 research articles, 1 systematic review (SR) article, and 2 narrative review articles.
Two cohort studies were gathered, "Chinese Herbal Decoction Based on Syndrome Differentiation as Mainte- Though not so many RCTs were gathered in this issue, fortunately, many design clinical studies were included. The quality of trials of TCM must be improved urgently through clinical methodology training, rigid protocol design, transparent and clear trial result reporting, and so forth. Some standard guidelines, for example, Consolidated Standards of Reporting Trials (CONSORT), would be valuable for the researchers for conducting TCM clinical trials. We, the editors, appeal that more proper designed clinical trials on long term major outcomes should be funded. Hopefully, this special issue will give helpful insights to scientists, physicians, and patients and will also be able to make a progress in the field of TCM clinical studies.
